Data further support clinical exploration of
nab-sirolimus in combination with endocrine therapy for
hormone-driven cancers, as is currently being investigated for
patients with endometrioid-type endometrial cancer in a Phase 2
trial
Data highlight potential for synergy to
enhance anti-cancer effects and overcome resistance in non-small
cell lung cancer
LOS
ANGELES, April 9, 2024 /PRNewswire/ -- Aadi
Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision
oncology company focused on developing and commercializing
therapies for cancers with alterations in the mTOR pathway, today
announced it will present new non-clinical data that highlight the
combinability of nab-sirolimus and its potential for synergy
to enhance anti-cancer effects and overcome resistance. These data
will be presented during poster sessions at the American
Association for Cancer Research (AACR) Annual Meeting in
San Diego, CA, taking place
April 5-10, 2024.
Poster presentation details and abstract highlights include:
Title: "Evaluation of nab-sirolimus in combination
with fulvestrant or PI3K pathway inhibitors to overcome resistance
in breast cancer cell lines"
Presenting Author:
Shihe Hou, PhD
Session Title: Reversal of Drug Resistance
Poster Number: Poster Section 25; Poster 6
Date/Time: Wednesday, April 10, 2024, 9:00 AM – 12:30
PM
- Fulvestrant, the selective estrogen receptor degrader and PI3K
inhibitors, such as alpelisib, have demonstrated efficacy in
patients with HR+ PI3K-mutated breast cancer; however,
resistance still occurs
- nab-sirolimus enhanced the cytotoxic effects of
fulvestrant in HR+ breast cancer cells and PI3Ki in both HR+ and
HR- breast cancer cells
- The addition of nab-sirolimus to endocrine therapy or
PI3K-AKT-mTOR pathway inhibitors may mutually overcome mechanisms
of resistance induced by single-agent treatments
- These data further support the combination of
nab-sirolimus with endocrine therapy for hormone-driven
cancers, as is currently being investigated in patients with
advanced or recurrent endometrioid endometrial cancer in a Phase 2
study (NCT05997017)
Title: "Correlation of nab-sirolimus tumor drug levels
and improved tumor suppression in KRAS G12C non-small cell lung
cancer xenografts treated with nab-sirolimus in combination with
KRAS inhibitors"
Presenting Author: Shihe Hou, PhD
Session Title: Targeting Kinase and ERK Pathways
Poster Number: Poster Section 46; Poster 3
Date/Time: Tuesday, April 9, 1:30 – 5:00 PM
- Corresponding with greater antitumor activity,
nab-sirolimus was associated with higher intratumoral drug
concentration and stronger mTOR target suppression than everolimus
when the agents were combined with KRAS G12C inhibitors
- These findings suggest more efficient tumor-targeting
with nab-sirolimus plus a KRAS G12C inhibitor may lead
to improved target inhibition and improved clinical outcomes
About Aadi Bioscience
Aadi is a
commercial-stage precision oncology company focused on the
development and commercialization of therapies for cancers with
alterations in the mTOR pathway, a key regulator of cell growth and
cancer progression. To unlock the full potential of mTOR
inhibition, Aadi uniquely combines nanoparticle albumin-bound
(nab) technology with the potent mTOR inhibitor, sirolimus.
Aadi received FDA approval and commercializes FYARRO® for the
treatment of adult patients with locally advanced unresectable or
metastatic malignant perivascular epithelioid cell tumor
(PEComa).
Aadi is exploring nab-sirolimus in PRECISION1, a Phase 2
tumor-agnostic registration-intended trial in mTOR inhibitor-naïve
malignant solid tumors harboring TSC1 or TSC2
inactivating alterations. Aadi is also exploring
nab-sirolimus in two single-indication Phase 2 trials for
difficult-to-treat mTOR-driven cancers: neuroendocrine tumors
(NETs), and advanced or recurrent endometrioid-type endometrial
cancer (EEC) in combination with letrozole. More information on the
Company's development pipeline is available on the Aadi website at
www.aadibio.com and connect with us on Twitter and LinkedIn.
Forward-Looking Statements
This press release
contains certain forward-looking statements regarding the business
of Aadi Bioscience that are not a description of historical facts
within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements are based on the Company's
current beliefs and expectations and may include, but are not
limited to, statements relating to: expectations regarding the
beneficial characteristics, safety, efficacy and therapeutic
effects of FYARRO; expectations regarding the clinical responses
and safety profile, regulatory approval and commercialization; and
the sufficiency of the Company's existing capital resources and the
expected timeframe to fund the Company's future operating expenses
and capital expenditure requirements. Actual results could differ
materially from those anticipated in such forward-looking
statements as a result of these risks and uncertainties, which
include, without limitation, those associated with the
uncertainties associated with the clinical development and
regulatory approval of FYARRO in additional indications; the risk
that non-clinical results may not be reproduced and do not
necessarily predict clinical results; the risk that unforeseen
adverse reactions or side effects may occur in the course of
commercializing, developing and testing FYARRO; and risks related
to the Company's estimates regarding future expenses, capital
requirements and need for additional financing.
Additional risks and uncertainties that could cause actual
outcomes and results to differ materially from those contemplated
by the forward-looking statements are included in the Company's
Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including under the caption
"Item 1A. Risk Factors," and elsewhere in Aadi's reports and other
documents that Aadi has filed, or will file, with the SEC from time
to time and available at www.sec.gov.
All forward-looking statements in this press release are current
only as of the date hereof and, except as required by applicable
law, Aadi undertakes no obligation to revise or update any
forward-looking statement, or to make any other forward-looking
statements, whether as a result of new information, future events
or otherwise. All forward-looking statements are qualified in their
entirety by this cautionary statement. This cautionary statement is
made under the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995.
Contact:
IR@aadibio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aadi-bioscience-to-present-new-non-clinical-data-highlighting-combinability-of-nab-sirolimus-at-the-american-association-for-cancer-research-aacr-annual-meeting-302111705.html
SOURCE Aadi Bioscience